First clinical experience with fractionated intracavitary radioimmunotherapy using [ 177 Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study.

Wolfgang RollMichael MütherGuido BöningAstrid DelkerNils WarnekeFranz-Josef GildehausMichael SchäfersWalter StummerReinhard ZeidlerHans-Jürgen ReulenLars Stegger

Published in: EJNMMI research (2023)

Lu]Lu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.

Keyphrases

clinical trial
study protocol
cross sectional
phase ii
mesenchymal stem cells
bone marrow
drug induced